Log In or Create Account
Resistance Mutations
Podcasts
Key Slides
Question of the Week
CROI
RWHAP Clinical Conference
Donate
Contact
Advanced Search
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
Did You Know?
FAQs
Fellow/Student Resources
Fellow/Student Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Menu
Antiretroviral Guidelines Panel
All
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
Resistance Mutations
Podcasts
Key Slides
Question of the Week
CROI
RWHAP Clinical Conference
Donate
Contact
CME Courses
HIV In-Person and Virtual Courses
Current On-Demand Courses
About Courses
CME Webinars
Upcoming Webinars
Current On-Demand Webinars
MATE Act CME
About Webinars
Dialogues
Upcoming IAS–USA Dialogues
On-Demand Dialogues
About Dialogues
Topics In Antiviral Medicine
Current Issues for CME
Previous Issues
TAM
Policies and Practices
Permission Request Form
Did You Know?
FAQs
Fellow/Student Resources
Fellow/Student Resources
IAS-USA Guidelines
On-Demand Webcasts
Research Collaborations
Additional Resources
About
Scientific Leadership Board
IAS-USA Leadership Award Recipients
Core Faculty
Mission
Staff
CME
Funding Information
Careers
Website Policies
Governance
FAQs
Practice Question of the Week
April 22, 2024: Prevention of Bacterial Sexually Transmitted Infections
Which of the following statements about prevention of bacterial sexually transmitted infections (STIs) is TRUE?
A. The meningococcal type B (4CMenB) vaccine significantly reduced the rate of gonorrhea infections among men who have sex with men (MSM)
B. Despite an increase in sexual risk among MSM and transgender women newly starting doxycycline postexposure prophylaxis (doxy-PEP), bacterial STI rates fell by approximately half in the
Evaluation of Doxycycline Post-exposure Prophylaxis to Reduce Sexually Transmitted Infections in PrEP Users and HIV-infected Men Who Have Sex With Men
study
C. Doxycycline was present in the majority of hair samples collected among women in the dPEP-KE (Doxycycline PEP for Prevention of Sexually Transmitted Infections Among Kenyan Women Using HIV PrEP) study, suggesting that biologic factors explain the lack of doxy-PEP efficacy in women
D. In the year after the implementation of doxy-PEP guidelines in San Francisco, rates of chlamydia, syphilis, and gonorrhea in MSM and transgender women fell by half
Register Now
View Archived Questions
Leave Feedback
Subscribe
CLOSE